iron sucrose + epoetin beta

Iron sucrose + epoetin beta is a combination therapy involving two agents: iron sucrose, an intravenous iron preparation, and epoetin beta, a recombinant human erythropoietin analog. Iron sucrose provides a readily bioavailable source of iron for hemoglobin synthesis, while epoetin beta stimulates erythropoiesis by acting as an agonist at the erythropoietin receptor on erythroid progenitor cells in the bone marrow. The combination is used primarily in the treatment of moderate to severe anemia when rapid hematologic response is required, especially in patients with iron deficiency anemia, anemia of chronic disease, or when oral iron is ineffective or intolerable. This combination is frequently used in chronic kidney disease, perioperative settings, pregnancy-related anemia, or for managing postoperative anemia, to raise hemoglobin more rapidly and efficiently than iron or erythropoietin alone. The combination exploits the mechanistic synergy of iron delivery for hemoglobin production and direct erythroid stimulation by epoetin beta[1][2][3][4].

Brand names

Neo-Recormon + Venofer

Other names

Epoetin and intravenous iron sucrose combination therapyErythropoietin and intravenous iron sucrose combination therapy